JP Morgan Chase
SIOX

JP Morgan Chase’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

JP Morgan Chase’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-33,425
Closed -$1.8M – 5632
2017
Q3 		$1.8M Buy
33,425
+27,950
+511% +$4.72M ﹤0.01% 3218
2017
Q2 		$1.02M Buy
+5,475
New +$960K ﹤0.01% 3420

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase's SIOX Position: Q4 2021 in Review

JP Morgan Chase sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 1,015 shares — an estimated $2K sold.

JP Morgan Chase first reported a position in SIOX in Q2 2015 and held it in 19 quarters. The position peaked at $21.4M in Q2 2017. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • JP Morgan Chase reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 1,015 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $2K.
  • JP Morgan Chase first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 19 quarters.
  • JP Morgan Chase's Sio Gene Therapies Inc. Common Stock position peaked at $21.4M in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.